The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 14, 2018

Filed:

Feb. 26, 2015
Applicant:

Incarda Therapeutics, Inc., San Francisco, CA (US);

Inventors:

Carlos A. Schuler, Cupertino, CA (US);

Rangachari Narasimhan, Saratoga, CA (US);

Assignee:

InCarda Therapeutics, Inc., Newark, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 9/06 (2006.01); A61P 9/00 (2006.01); A61K 31/277 (2006.01); A61K 9/00 (2006.01); A61K 31/4458 (2006.01); A61K 31/554 (2006.01); A61K 31/18 (2006.01); A61K 31/216 (2006.01); A61K 31/7076 (2006.01); A61M 11/00 (2006.01); A61K 31/445 (2006.01); A61K 31/55 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0078 (2013.01); A61K 31/18 (2013.01); A61K 31/216 (2013.01); A61K 31/445 (2013.01); A61K 31/4458 (2013.01); A61K 31/55 (2013.01); A61K 31/554 (2013.01); A61K 31/7076 (2013.01); A61M 11/00 (2013.01); Y10S 514/821 (2013.01);
Abstract

Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.


Find Patent Forward Citations

Loading…